Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19. Show more
Location: 1 Pluckemin Way - Suite 103, New Jersey, 07921, United States | Website: www.tymeinc.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
1.018B
52 Wk Range
$N/A - $N/A
Previous Close
$0.29
Open
$0.29
Volume
2,678,186
Day Range
$0.28 - $0.32
Enterprise Value
0.00
Cash
159.3M
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|